UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3

PloS one, 2013-11, Vol.8 (11), p.e79655

2013

Link zum Volltext

Verfügbarkeit prüfen

miR-221 promotes tumorigenesis in human triple negative breast cancer cells

PloS one, 2013-04, Vol.8 (4), p.e62170

2013

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer

European urology, 2014-07, Vol.66 (1), p.145-155

2014

Link zum Volltext

Verfügbarkeit prüfen

Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer

Cancer research (Chicago, Ill.), 2011-09, Vol.71 (17), p.5838-5849

2011

Link zum Volltext

Verfügbarkeit prüfen

A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis

Clinical cancer research, 2011-04, Vol.17 (8), p.2301-2313

2011

Link zum Volltext

Verfügbarkeit prüfen

Linking Nek6 to p53-induced senescence

Cell cycle (Georgetown, Tex.), 2011-01, Vol.10 (1), p.23-22

Yin, Min-Jean

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

PloS one, 2012-10, Vol.7 (10), p.e48402

2012

Link zum Volltext

Verfügbarkeit prüfen

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

Clinical cancer research, 2011-08, Vol.17 (16), p.5432-5442

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting the mTOR pathway in tumor malignancy

Current cancer drug targets, 2013-03, Vol.13 (3), p.267

2013

Link zum Volltext

Verfügbarkeit prüfen

The Serine/Threonine Kinase Nek6 Is Required for Cell Cycle Progression through Mitosis

The Journal of biological chemistry, 2003-12, Vol.278 (52), p.52454-52460

2003

Link zum Volltext

Verfügbarkeit prüfen

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2189-2199

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Journal of medicinal chemistry, 2016-03, Vol.59 (5), p.2005-2024

2016

Link zum Volltext

Verfügbarkeit prüfen

Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target

Molecular cancer research, 2010-05, Vol.8 (5), p.717-728

2010

Link zum Volltext

Verfügbarkeit prüfen

The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β

Nature (London), 1998-11, Vol.396 (6706), p.77-80

1998

Link zum Volltext

Verfügbarkeit prüfen

Retraction notice to “A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells”

Cancer letters, 2018-05, Vol.422, p.132-132

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

Clinical cancer research, 2014-02, Vol.20 (3), p.631-643

2014

Link zum Volltext

Verfügbarkeit prüfen

Sulindac Inhibits Activation of the NF-κB Pathway

The Journal of biological chemistry, 1999-09, Vol.274 (38), p.27307-27314

1999

Link zum Volltext

Verfügbarkeit prüfen

Differential Transcriptional Activation by Human T-Cell Leukemia Virus Type 1 Tax Mutants Is Mediated by Distinct Interactions with CREB Binding Protein and p300

Molecular and Cellular Biology, 1998-04, Vol.18 (4), p.2392-2405

1998

Link zum Volltext

Verfügbarkeit prüfen

Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone

Journal of medicinal chemistry, 2010-01, Vol.53 (1), p.499-503

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model

The Journal of pharmacology and experimental therapeutics, 2011-09, Vol.338 (3), p.964

2011

Link zum Volltext

Verfügbarkeit prüfen

Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors

Bioorganic & medicinal chemistry letters, 2012-08, Vol.22 (15), p.5114-5117

2012

Link zum Volltext

Verfügbarkeit prüfen

IκB Kinase α (IKKα) Regulation of IKKβ Kinase Activity

Molecular and Cellular Biology, 2000-05, Vol.20 (10), p.3655-3666

2000

Link zum Volltext

Verfügbarkeit prüfen

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

ACS medicinal chemistry letters, 2013-01, Vol.4 (1), p.91-97

2013

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)

Journal of medicinal chemistry, 2011-12, Vol.54 (24), p.8490-8500

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Englisch
(62)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(29)
Humans
(25)
Animals
(15)
Cell Line, Tumor
(14)
Mice
(12)
Oncology
(12)
Antineoplastic Agents - Pharmacology
(11)
Biochemistry & Molecular Biology
(9)
Biological And Medical Sciences
(9)
Hsp90 Heat-Shock Proteins - Antagonists & Inhibitors
(9)
Medical Sciences
(9)
Pharmacology & Pharmacy
(9)
Chemistry, Medicinal
(8)
Female
(8)
Mutation
(8)
Pharmacology. Drug Treatments
(8)
Cell Biology
(7)
Tumors
(7)
Xenograft Model Antitumor Assays
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3

miR-221 promotes tumorigenesis in human triple negative breast cancer cells

Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer

Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer

A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis

Linking Nek6 to p53-induced senescence

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

Targeting the mTOR pathway in tumor malignancy

The Serine/Threonine Kinase Nek6 Is Required for Cell Cycle Progression through Mitosis

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target

The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β

Retraction notice to “A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells”

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

Sulindac Inhibits Activation of the NF-κB Pathway

Differential Transcriptional Activation by Human T-Cell Leukemia Virus Type 1 Tax Mutants Is Mediated by Distinct Interactions with CREB Binding Protein and p300

Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model

Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors

IκB Kinase α (IKKα) Regulation of IKKβ Kinase Activity

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)

Suchergebnisse filtern